Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy
暂无分享,去创建一个
F. Behm | S. Raimondi | W. Evans | A. Look | M. Hancock | D. Williams | G. Rivera | S. Murphy | G. Dahl | W. Crist | L. Kun | S. Raimondi | M. Abromowitch | M. Hancock | A. T. Look | G. K. Rivera | C.-H. Pui | M. Abromowitch | J. Mirro | J. S. Ochs | S. B. Murphy | G. V. Dahl | D. K. Kalwinsky | J. V. Simone | W. M. Crist | S. C. Raimondi | F. G. Behm | D. L. Williams | M. L. Hancock | W. E. Evans | L. E. Kun | J. Mirro | Pui Ch | DorothyL. Williams | F. Behm | J. Simone | J. Ochs | D. Kalwinsky | L. Kun | G. Dahl | C. Pui | William E. Evans
[1] N R Schneider,et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Behm,et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study , 1990 .
[3] Jonathan J. Shuster,et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study , 1990 .
[4] M. Borowitz,et al. Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1989, Blood.
[5] H. Jürgens,et al. Rapidly rotating combination chemotherapy in childhood acute lymphoblastic leukemia: preliminary results of a randomized comparison with conventional treatment. , 1988, Leukemia.
[6] A. Look,et al. The cytogenetics of childhood leukemia: clinical and biologic implications. , 1988, Pediatric clinics of North America.
[7] A. Look,et al. Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] I. Pastan,et al. Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.
[9] R. Gelber,et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.
[10] D. Williams,et al. A direct bone marrow chromosome technique for acute lymphoblastic leukemia. , 1984, Cancer genetics and cytogenetics.
[11] Goldie Jh,et al. Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982 .
[12] A. Goldin,et al. The chemotherapy of human and animal acute leukemia. , 1971, Cancer chemotherapy reports.
[13] R. H. Levin,et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. , 1965, Blood.
[14] J. Shuster,et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1990, Blood.
[15] S. Lipshultz,et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. , 1990, The Journal of pediatrics.
[16] G. Henze,et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990, Haematology and blood transfusion.
[17] A. Cork,et al. Molecular heterogeneity in acute leukemia lineage switch. , 1989, Blood.
[18] F. Behm,et al. Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Pui,et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. , 1988, Medical and pediatric oncology.
[20] Cyclophosphamide and bone marrow transplantation. , 1988, The New England journal of medicine.
[21] C. Pui,et al. Limiting toxicities during intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. , 1987, Haematology and blood transfusion.
[22] Improvement in treatment for children with acute lymphoblastic leukaemia , 1986, Indian journal of pediatrics.
[23] C. Pui,et al. Early results of intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. , 1986, Medical and pediatric oncology.
[24] J. Pullen,et al. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. , 1986, Medical and pediatric oncology.
[25] H. Sather. Age at diagnosis in childhood acute lymphoblastic leukemia. , 1986, Medical and pediatric oncology.
[26] G. Rivera,et al. Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: implications for treatment outcome. , 1985, Leukemia research.
[27] H. Klinger,et al. ISCN 1985 : an international system for human cytogenetic nomenclature (1985) : report of the Standing Committee on Human Cytogenetic Nomenclature , 1985 .
[28] M. Seip,et al. Intermediate dose methotrexate in childhood acute lymphocytic leukemia , 1984 .
[29] J H Goldie,et al. Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.
[30] A. Bleyer. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. , 1977, Cancer treatment reports.